- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00586885
Effects of Alanine in Patients With Nonalcoholic Steatohepatitis
October 9, 2012 updated by: Keith D Lindor, M.D.
A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis
Purpose of this study is to assess the therapeutic efficacy of L-alanine in improving biological and histological findings by administrating 6-18g/day L-alanine for one year.
We will also assess the safety and toxicity profile of long-term administration of L-alanine.
Study Overview
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females, age between 18 and 75
- Histological diagnosis of steatohepatitis with or without fibrosis made within one year of entry
- Transaminase levels (ALT or AST) more than 1.5 times the upper normal limit on at least two occasions with one assessment in three months or more prior to treatment of this study
- Previous and current alcohol consumption less than 20g per day by patient-provided information.
- Written informed consent specific for this protocol available prior to entry.
- Patients with diabetes and on stable medical management for six months prior to entry and an anticipated stable program throughout the study will be eligible. Medications that may be used include insulin, biguanides and sulfonylureas.
- Patients with congestive heart failure, hypertension and arrhythmia controlled by medications and without cardiac episodes during the past 6 months will be eligible.
Exclusion Criteria:
- Any causes for liver disease other than nonalcoholic steatohepatitis that are confirmed by patient history, laboratory data, or histological data
Decompensated liver disease based on laboratory data, or clinical manifestations
- Hemoglobin <11.0g/dl for male, <10.0 g/dl for female
- White blood cells <2000 /mm3
- Platelet count <50,000/mm3
- Prothrombin time >INR 1.5
- Total Bilirubin >2.0 g/dl
- Albumin <3.0/dl
- The presence of ascites
- The presence of bleeding varices
- The presence of spontaneous encephalopathy
- Any previous experimental treatment of NASH within the past 3 months such as betaine, thiazolidinediones, α-tocopherol, or UDCA
- Pre-existing diseases/situations that could interfere with the results or the completion of this trial.
Uncontrolled diabetes mellitus meeting following criteria in previous 3 months
- Fasting blood sugar >200 mg/dl
- Hemoglobin A1c >12%
- Renal or liver transplant patients
Renal dysfunction in previous 3 months
a) CCr <50ml/min
- Severe cardiovascular dysfunction in previous 6 months
- Congestive heart failure
- Uncontrolled hypertension
- Uncontrolled arrhythmia
- Patients with hyperlipidemia on a medical program for control of lipids which has had a change in drug treatment in the proceeding six months or with anticipated changes in the year of the study.
- Chronic pulmonary disease such as COPD requiring corticosteroid therapy in previous 3 months
- Active autoimmune or immunologically mediated diseases including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel diseases in previous 12 months
- Previous (in three years) or present malignant disease except for non-melanoma skin cancer
- Untreated hyperthyroidism and hypothyroidism
- Substance abuse of oral, I.V., or inhaled drugs.
- If patients with history of substance abuse are considered as participants in this trial, patients must have abstained from using the abused substance for at least one year.
- Patients receiving methadone within the past 6 months are also excluded.
- Any other conditions that would make the patients unsuitable for enrollment in the opinion of the investigator in terms of interference in completing the trial and/or results of trial.
- Pregnant women
- Unwillingness of patients and /or partner to use contraceptive during treatment and for 3 months after discontinuation of treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Single arm, active treatment
|
6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety and tolerability of long-term L-alanine supplementation and the therapeutic efficacy of long-term L-alanine supplementation by evaluating liver biochemistry and histological findings.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the effect of L-alanine on gene profiles, anti-oxidant response and inflammatory response in hepatocytes. Evaluate possible correlation between therapeutic efficacy and gene profiles altered by L-alanine supplementation
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Suzuki A, Charlton MR, Lymp JF, et al. A pilot study: No therapeutic effect of L-alanine in patients with nonalcoholic steatohepatitis. Food and Nutrition Sciences 2: 67-73, 2010.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2004
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
December 21, 2007
First Posted (Estimate)
January 7, 2008
Study Record Updates
Last Update Posted (Estimate)
October 11, 2012
Last Update Submitted That Met QC Criteria
October 9, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1753-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on L-alanine
-
Meshalkin Research Institute of Pathology of CirculationCompletedCoronary Artery DiseaseRussian Federation
-
Emory UniversityEmmaus Medical, Inc.Completed
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
University of OregonNational Institute on Aging (NIA); Oregon Health and Science University; University... and other collaboratorsUnknownQuality of Life | Muscle AtrophyUnited States
-
Children's Hospital Medical Center, CincinnatiUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedDevelopment | Biological Markers | Nutrition | Short Bowel Syndrome | Bloodstream InfectionsUnited States
-
Vincent Martin, MDTargeted Medical PharmaTerminated
-
Nanjing Medical UniversityBeijing Anzhen Hospital; Second Affiliated Hospital of Nanchang UniversityRecruitingAcute Aortic Syndrome | Aortic DissectioChina
-
Yuejiang LiuCompletedCoronary Heart Disease | Rheumatic Heart DiseaseChina
-
Yonsei UniversityUnknownAortic Valve StenoisKorea, Republic of
-
Augusta UniversityTerminatedDietary Fructose IntoleranceUnited States